CN112280803B - Construction method of Tks4 gene knock-out mouse - Google Patents
Construction method of Tks4 gene knock-out mouse Download PDFInfo
- Publication number
- CN112280803B CN112280803B CN202011164525.0A CN202011164525A CN112280803B CN 112280803 B CN112280803 B CN 112280803B CN 202011164525 A CN202011164525 A CN 202011164525A CN 112280803 B CN112280803 B CN 112280803B
- Authority
- CN
- China
- Prior art keywords
- tks4
- mouse
- gene
- sgrna9
- sgrna1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000003209 gene knockout Methods 0.000 title claims abstract description 33
- 238000010276 construction Methods 0.000 title claims abstract description 17
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 25
- 239000002773 nucleotide Substances 0.000 claims abstract description 15
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 15
- 235000013601 eggs Nutrition 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
- 238000011144 upstream manufacturing Methods 0.000 claims description 3
- 238000010353 genetic engineering Methods 0.000 abstract description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 47
- 108020004414 DNA Proteins 0.000 description 23
- 241000699670 Mus sp. Species 0.000 description 21
- 108091027544 Subgenomic mRNA Proteins 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000010362 genome editing Methods 0.000 description 5
- 238000011813 knockout mouse model Methods 0.000 description 5
- 108091033409 CRISPR Proteins 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241000581650 Ivesia Species 0.000 description 2
- 102100038871 SH3 and PX domain-containing protein 2B Human genes 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 101150028074 2 gene Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 208000028935 Frank-Ter Haar syndrome Diseases 0.000 description 1
- 101000663843 Homo sapiens SH3 and PX domain-containing protein 2B Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 101710186098 SH3 and PX domain-containing protein 2B Proteins 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000001243 pseudopodia Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Environmental Sciences (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Toxicology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention provides a construction method of a Tks4 gene knock-out mouse, belonging to the technical field of genetic engineering, wherein a Tks4 gene of a mouse is knocked out by utilizing sgRNA1 and sgRNA9 to obtain a Tks4 gene knock-out mouse; the nucleotide sequence of the sgRNA1 is shown in SEQ ID No.1, and the nucleotide sequence of the sgRNA9 is shown in SEQ ID No. 2. The invention utilizes sgRNA1 and sgRNA9 to knock out the Tks4 gene of a mouse, and obtains a Tks4 gene knock-out mouse.
Description
Technical Field
The invention belongs to the technical field of genetic engineering, and particularly relates to a construction method of a Tks4 gene knock-out mouse.
Background
Tks4(Tyrosine kinase substrate with four SH3 domains) is a protein product of SH3PXD2B (also called Tks4 gene) which is a disease-causing gene of a recessive genetic disease-FTHS syndrome (Frank-Ter Haar syndrome), and has 1 PX structural domain and 4 SH3 structural domains. Previous studies have shown that Tks4 plays a major role in pseudopodia formation and motility, actin cytoskeleton remodeling, reactive oxygen species production, and adipose tissue generation and differentiation. The Tks4 gene is located on chromosome 11 of the mouse genome, approximately spanning the 80.4kb genome range, and contains 13 exons and 12 introns. As an important pathogenic factor, the prior art has not reported how to knock out the Tks4 gene.
Disclosure of Invention
In view of the above, the invention aims to provide a construction method of a Tks4 gene knock-out mouse, and the invention utilizes sgRNA1 and sgRNA9 to knock out the Tks4 gene of the mouse, so as to obtain a Tks4 gene knock-out mouse.
In order to achieve the above purpose, the invention provides the following technical scheme:
the invention provides a construction method of a Tks4 gene knock-out mouse, which comprises the steps of knocking out a Tks4 gene of a mouse by utilizing sgRNA1 and sgRNA9 to obtain a Tks4 gene knock-out mouse;
the nucleotide sequence of the sgRNA1 is shown in SEQ ID No.1, and the nucleotide sequence of the sgRNA9 is shown in SEQ ID No. 2.
Preferably, the mass ratio of the sgRNA1 to the sgRNA9 is 0.5-1.5: 0.5-1.5.
Preferably, the mass ratio of the sgRNA1 to the sgRNA9 is 1: 1.
Preferably, the method further comprises the following steps: cas9mRNA, sgRNA1 and sgRNA9 are introduced into the nucleus of a mouse fertilized egg cell to obtain a Tks4 gene knock-out mouse.
Preferably, the nucleotide sequence of the Cas9mRNA is shown as SEQ ID No. 3.
Preferably, the mass ratio of the Cas9mRNA to the sgRNA1 and the sgRNA9 is 1.5-2.5: 0.3-0.8.
Preferably, the mass ratio of the Cas9mRNA to the sgRNA1 and the sgRNA9 is 2:0.5: 0.5.
Preferably, Tks4 gene knock-out mice are identified by using a primer pair, wherein the nucleotide sequences of the upstream primer and the downstream primer of the primer pair are shown as SEQ ID No.4 and 5 respectively.
The invention provides a construction method of a Tks4 gene knock-out mouse, which comprises the steps of knocking out a Tks4 gene of a mouse by utilizing sgRNA1 and sgRNA9 to obtain a Tks4 gene knock-out mouse; the sgRNA1 has a nucleotide sequence shown in SEQ ID No.1, and the sgRNA9 has a nucleotide sequence shown in SEQ ID No. 2.
The mechanism of knocking out the Tks4 gene is as follows: after Cas9mRNA and sgRNA1 and sgRNA9 are injected into the nucleus of fertilized eggs, Cas9mRNA is translated to generate Cas9 protein, Cas9 protein binds to sgRNA1 or sgRNA9 respectively, and is targeted to bind to intron No.2 and intron No.3 of Tks4 gene respectively by virtue of the sequence specificity of sgRNA1 or sgRNA9, so that DNA double-strand cleavage is formed in the two regions, and the exon No.3 region between intron No.2 and intron No.3 is deleted from chromosome 11, so that Tks4 protein cannot be expressed correctly.
Drawings
Fig. 1 is a test of sgRNA gene editing efficiency;
fig. 2 shows the results of in vitro transcription and purification of single-stranded sgrnas;
FIG. 3 is a schematic diagram of gene editing in Tks4 knockout mice;
FIG. 4 shows the genotype identification results of F0 mouse;
FIG. 5 shows the genotype identification results of F1 mouse;
FIG. 6 shows the detection of the knockout efficiency of Tks4 gene knockout mice.
Detailed Description
The invention provides a construction method of a Tks4 gene knock-out mouse, which comprises the steps of knocking out a Tks4 gene of a mouse by utilizing sgRNA1 and sgRNA9 to obtain a Tks4 gene knock-out mouse; the nucleotide sequence of the sgRNA1 is shown in SEQ ID No.1, and the nucleotide sequence of the sgRNA9 is shown in SEQ ID No. 2. In the invention, the mass ratio of the sgRNA1 to the sgRNA9 is preferably 0.5-1.5: 0.5-1.5, and more preferably 1: 1.
The sgRNA1 and sgRNA9 are designed according to the sequence characteristics of a Tks4 Gene (Gene ID is 268396) by using http:// criprp. mit. edu/website aiming at intron sequences on both sides of a No.3 exon of Tks4 and are used for knocking out the Tks4 Gene, wherein the sgRNA1 is designed according to a 3 'end intron region of the No.3 exon of Tks4, and the sgRNA9 is designed according to a 5' end intron region of the No.3 exon of Tks 4. The invention selects and cuts the exon No.3 for two reasons, the first reason, should lean to the front as much as possible while choosing and cutting the exon, the knockout effect reached after cutting is most obvious, the second reason, the exon cut can not be the multiple of 3 in length, otherwise may cause a new reading frame to produce, can not reach the goal of gene knockout completely, combine these two factors, the exon No.3 is the exon that the first length of the gene is not the multiple of 3, so is chosen as constructing and knocking off the target of the mouse. In the invention, the nucleotide sequence of the sgRNA1 is shown in SEQ ID No.1, and specifically comprises the following steps:
CTGTTGTAACTCGCCAATGA;
the nucleotide sequence of the sgRNA9 is shown in SEQ ID No.2, and specifically comprises the following steps:
TGGTCGTATAAAGATGGTGC。
in the present invention, the construction method of the Tks4 gene knock-out mouse preferably further comprises: cas9mRNA, sgRNA1 and sgRNA9 are introduced into mouse fertilized egg cell nucleus to obtain Tks4 gene knockout mouse. The source of the mouse is not particularly limited, and C57BL/6J mice which are used for gene knockout in a conventional way can be adopted, and C57BL/6J mice can be purchased.
In the present invention, the Cas9mRNA functions as: translation into Cas9 protein in fertilized eggs, followed by cleavage of the genomic DNA molecule by Cas9 protein under the guidance of the sgrnas. In the invention, the nucleotide sequence of the Cas9mRNA is shown as SEQ ID No.3, which is specifically as follows:
ATGGACAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGGCTGGGCCGTGATCACCGACGAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGACCGGCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTCGACAGCGGCGAAACAGCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAAGAACCGGATCTGCTATCTGCAAGAGATCTTCAGCAACGAGATGGCCAAGGTGGACGACAGCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGAAGAGGATAAGAAGCACGAGCGGCACCCCATCTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTACCCCACCATCTACCACCTGAGAAAGAAACTGGTGGACAGCACCGACAAGGCCGACCTGCGGCTGATCTATCTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGATCGAGGGCGACCTGAACCCCGACAACAGCGACGTGGACAAGCTGTTCATCCAGCTGGTGCAGACCTACAACCAGCTGTTCGAGGAAAACCCCATCAACGCCAGCGGCGTGGACGCCAAGGCCATCCTGTCTGCCAGACTGAGCAAGAGCAGACGGCTGGAAAATCTGATCGCCCAGCTGCCCGGCGAGAAGAAGAATGGCCTGTTCGGAAACCTGATTGCCCTGAGCCTGGGCCTGACCCCCAACTTCAAGAGCAACTTCGACCTGGCCGAGGATGCCAAACTGCAGCTGAGCAAGGACACCTACGACGACGACCTGGACAACCTGCTGGCCCAGATCGGCGACCAGTACGCCGACCTGTTTCTGGCCGCCAAGAACCTGTCCGACGCCATCCTGCTGAGCGACATCCTGAGAGTGAACACCGAGATCACCAAGGCCCCCCTGAGCGCCTCTATGATCAAGAGATACGACGAGCACCACCAGGACCTGACCCTGCTGAAAGCTCTCGTGCGGCAGCAGCTGCCTGAGAAGTACAAAGAGATTTTCTTCGACCAGAGCAAGAACGGCTACGCCGGCTACATTGACGGCGGAGCCAGCCAGGAAGAGTTCTACAAGTTCATCAAGCCCATCCTGGAAAAGATGGACGGCACCGAGGAACTGCTCGTGAAGCTGAACAGAGAGGACCTGCTGCGGAAGCAGCGGACCTTCGACAACGGCAGCATCCCCCACCAGATCCACCTGGGAGAGCTGCACGCCATTCTGCGGCGGCAGGAAGATTTTTACCCATTCCTGAAGGACAACCGGGAAAAGATCGAGAAGATCCTGACCTTCCGCATCCCCTACTACGTGGGCCCTCTGGCCAGGGGAAACAGCAGATTCGCCTGGATGACCAGAAAGAGCGAGGAAACCATCACCCCCTGGAACTTCGAGGAAGTGGTGGACAAGGGCGCTTCCGCCCAGAGCTTCATCGAGCGGATGACCAACTTCGATAAGAACCTGCCCAACGAGAAGGTGCTGCCCAAGCACAGCCTGCTGTACGAGTACTTCACCGTGTATAACGAGCTGACCAAAGTGAAATACGTGACCGAGGGAATGAGAAAGCCCGCCTTCCTGAGCGGCGAGCAGAAAAAGGCCATCGTGGACCTGCTGTTCAAGACCAACCGGAAAGTGACCGTGAAGCAGCTGAAAGAGGACTACTTCAAGAAAATCGAGTGCTTCGACTCCGTGGAAATCTCCGGCGTGGAAGATCGGTTCAACGCCTCCCTGGGCACATACCACGATCTGCTGAAAATTATCAAGGACAAGGACTTCCTGGACAATGAGGAAAACGAGGACATTCTGGAAGATATCGTGCTGACCCTGACACTGTTTGAGGACAGAGAGATGATCGAGGAACGGCTGAAAACCTATGCCCACCTGTTCGACGACAAAGTGATGAAGCAGCTGAAGCGGCGGAGATACACCGGCTGGGGCAGGCTGAGCCGGAAGCTGATCAACGGCATCCGGGACAAGCAGTCCGGCAAGACAATCCTGGATTTCCTGAAGTCCGACGGCTTCGCCAACAGAAACTTCATGCAGCTGATCCACGACGACAGCCTGACCTTTAAAGAGGACATCCAGAAAGCCCAGGTGTCCGGCCAGGGCGATAGCCTGCACGAGCACATTGCCAATCTGGCCGGCAGCCCCGCCATTAAGAAGGGCATCCTGCAGACAGTGAAGGTGGTGGACGAGCTCGTGAAAGTGATGGGCCGGCACAAGCCCGAGAACATCGTGATCGAAATGGCCAGAGAGAACCAGACCACCCAGAAGGGACAGAAGAACAGCCGCGAGAGAATGAAGCGGATCGAAGAGGGCATCAAAGAGCTGGGCAGCCAGATCCTGAAAGAACACCCCGTGGAAAACACCCAGCTGCAGAACGAGAAGCTGTACCTGTACTACCTGCAGAATGGGCGGGATATGTACGTGGACCAGGAACTGGACATCAACCGGCTGTCCGACTACGATGTGGACCATATCGTGCCTCAGAGCTTTCTGAAGGACGACTCCATCGACAACAAGGTGCTGACCAGAAGCGACAAGAACCGGGGCAAGAGCGACAACGTGCCCTCCGAAGAGGTCGTGAAGAAGATGAAGAACTACTGGCGGCAGCTGCTGAACGCCAAGCTGATTACCCAGAGAAAGTTCGACAATCTGACCAAGGCCGAGAGAGGCGGCCTGAGCGAACTGGATAAGGCCGGCTTCATCAAGAGACAGCTGGTGGAAACCCGGCAGATCACAAAGCACGTGGCACAGATCCTGGACTCCCGGATGAACACTAAGTACGACGAGAATGACAAGCTGATCCGGGAAGTGAAAGTGATCACCCTGAAGTCCAAGCTGGTGTCCGATTTCCGGAAGGATTTCCAGTTTTACAAAGTGCGCGAGATCAACAACTACCACCACGCCCACGACGCCTACCTGAACGCCGTCGTGGGAACCGCCCTGATCAAAAAGTACCCTAAGCTGGAAAGCGAGTTCGTGTACGGCGACTACAAGGTGTACGACGTGCGGAAGATGATCGCCAAGAGCGAGCAGGAAATCGGCAAGGCTACCGCCAAGTACTTCTTCTACAGCAACATCATGAACTTTTTCAAGACCGAGATTACCCTGGCCAACGGCGAGATCCGGAAGCGGCCTCTGATCGAGACAAACGGCGAAACCGGGGAGATCGTGTGGGATAAGGGCCGGGATTTTGCCACCGTGCGGAAAGTGCTGAGCATGCCCCAAGTGAATATCGTGAAAAAGACCGAGGTGCAGACAGGCGGCTTCAGCAAAGAGTCTATCCTGCCCAAGAGGAACAGCGATAAGCTGATCGCCAGAAAGAAGGACTGGGACCCTAAGAAGTACGGCGGCTTCGACAGCCCCACCGTGGCCTATTCTGTGCTGGTGGTGGCCAAAGTGGAAAAGGGCAAGTCCAAGAAACTGAAGAGTGTGAAAGAGCTGCTGGGGATCACCATCATGGAAAGAAGCAGCTTCGAGAAGAATCCCATCGACTTTCTGGAAGCCAAGGGCTACAAAGAAGTGAAAAAGGACCTGATCATCAAGCTGCCTAAGTACTCCCTGTTCGAGCTGGAAAACGGCCGGAAGAGAATGCTGGCCTCTGCCGGCGAACTGCAGAAGGGAAACGAACTGGCCCTGCCCTCCAAATATGTGAACTTCCTGTACCTGGCCAGCCACTATGAGAAGCTGAAGGGCTCCCCCGAGGATAATGAGCAGAAACAGCTGTTTGTGGAACAGCACAAGCACTACCTGGACGAGATCATCGAGCAGATCAGCGAGTTCTCCAAGAGAGTGATCCTGGCCGACGCTAATCTGGACAAAGTGCTGTCCGCCTACAACAAGCACCGGGATAAGCCCATCAGAGAGCAGGCCGAGAATATCATCCACCTGTTTACCCTGACCAATCTGGGAGCCCCTGCCGCCTTCAAGTACTTTGACACCACCATCGACCGGAAGAGGTACACCAGCACCAAAGAGGTGCTGGACGCCACCCTGATCCACCAGAGCATCACCGGCCTGTACGAGACACGGATCGACCTGTCTCAGCTGGGAGGCGACTAA。
in the invention, the mass ratio of the Cas9mRNA to the sgRNA1 and the sgRNA9 is preferably 1.5-2.5: 0.3-0.8, and more preferably 2:0.5: 0.5.
In the present invention, after the Cas9mRNA, the sgRNA1 and the sgRNA9 are introduced into fertilized eggs of mice, the mice are obtained, and preferably identified by using primer pairs, the nucleotide sequences of the upstream and downstream primers of the primer pairs are respectively shown in SEQ id nos. 4 and 5, specifically as follows:
SEQ ID No.4:GAAGGGCATTCTAACACACCTGTCA;
SEQ ID No.5:CAGAGGCCAACCAAGAGAGAGAAGC。
in the invention, PCR amplification is carried out on the obtained rat tail tissue of the mouse by using the primer pair, and when the amplified fragment is 700-800bp, a Tks4 gene knock-out mouse is obtained. In the invention, the system used for PCR amplification comprises a system of 1 mu L of mouse tail DNA solution, 0.5 mu L of Taq enzyme, 1 mu L of dNTPs, 1 mu L of each primer and 10 mu L of Buffer, and 5.5 mu L of distilled water, wherein the total amount is 20 mu L; the reaction program used for the PCR amplification comprises: 94 ℃ for 2 min; 10s at 98 ℃, 30s at 67 ℃ (-0.7 ℃/cycle), 1kb/min at 68 ℃ and 15 cycles; 10s at 98 ℃, 30s at 56 ℃, 1kb/min at 68 ℃ and 25 cycles; 10min at 68 ℃; storing at 4 ℃.
The technical solutions provided by the present invention are described in detail below with reference to examples, but they should not be construed as limiting the scope of the present invention.
Example 1
Using UCATM(Universal CRISPRACTIVITY Assay) method the gene editing efficiency of sgRNA1 and sgRNA9 was examined in an in vitro acellular system, and the results are shown in FIG. 1.
The method is used for detecting the shearing efficiency of the sgRNA1, and the results of three experiments are respectively 25.42%; 26.34% and 38.08%. The shear efficiency of the sgRNA9 is detected by the method, and the results of three experiments are 23.36% respectively; 22.89% and 23.24%
Comparative example 1
sgRNA2-7 was designed based on the 3' intron region of exon 3 of Tks4, with the following sequence:
sgRNA2(SEQ ID No.6):TACCATGGAGCCGTCCCTCC;
sgRNA3(SEQ ID No.7):CATGCATACAGCATAGGACC;
sgRNA4(SEQ ID No.8):CAACATGTCGCTCTGTATTC;
sgRNA5(SEQ ID No.9):CGTGTGAGATACCACAAAAC;
sgRNA6(SEQ ID No.10):GTGGCTCATGCATACAGCAT;
sgRNA7(SEQ ID No.11):CAGAGCATACAAGAATTGAG。
sgRNA8/10-14 was designed from the 5' intron region of exon 3 of Tks4, the sequence is as follows:
sgRNA8(SEQ ID No.12):GCTCTACACCCGTGTCACAA;
sgRNA10(SEQ ID No.13):TGAGAATGGTCGTATAAAGA;
sgRNA11(SEQ ID No.14):AAGGAGGAACTGGGTCCCGG;
sgRNA12(SEQ ID No.15):GCCAGATCTGGGATGCAAAC;
sgRNA13(SEQ ID No.16):CATTTATAGGGATCCAAGAA;
sgRNA14(SEQ ID No.17):TGTTGTTGCTCATATATGAC。
the gene editing efficiency of sgRNA was examined in the same manner as in example 1, and the results are shown in fig. 1.
The cleavage efficiencies mediated by the different sgrnas are shown in table 1.
TABLE 1 cleavage efficiency mediated by different sgRNAs
sgRNA2 | sgRNA3 | sgRNA4 | sgRNA5 | sgRNA6 | sgRNA7 |
24.48% | 21.8% | 0.77% | 5.59% | 6.59% | 7.33% |
22.28% | 19.07% | 0.69% | 6.5% | 8.76% | 7.11% |
35.59% | 31.75% | 1.23% | 8.84% | 8.7% | 9.65% |
sgRNA8 | sgRNA10 | sgRNA11 | sgRNA12 | sgRNA13 | sgRNA14 |
10.09% | 12.33% | 16.97% | 5.94% | 6.67% | 22.7% |
9.76% | 13.38% | 18.41% | 6.13% | 7.99% | 23.4% |
10.17% | 14.85% | 19.87% | 6.57% | 8.42% | 23.9% |
As can be seen from example 1 and comparative examples, sgRNA1 and sgRNA9 had the highest DNA cleavage efficiency at the 3 'and 5' ends of exon 3 of Tks4, respectively, and therefore sgRNA1 and sgRNA9 were selected to knock out the Tks4 gene. The sgRNA1 and the sgRNA9 were separately transcribed in vitro to obtain purified single-stranded sgrnas (fig. 2) for subsequent fertilized egg injection experiments.
Example 2
The sgRNA1 and the sgRNA9 purified in example 1 were mixed in equal mass ratio to prepare a sgRNA solution with a concentration of 50 ng/. mu.L, and then mixed with 100 ng/. mu.L of Cas9mRNA, with the mixing ratio of sgRNA to Cas9mRNA being 1: 2. Mixing, injecting into mouse fertilized egg nuclei, culturing fertilized egg in vitro to embryo stage, transferring into surrogate mother mouse uterus, performing PCR identification in born mice, and determining whether gene editing of Tks4 gene of each mouse exists, wherein the specific editing is shown in FIG. 3.
After injection, six F0 mice were obtained in total, and PCR detection was performed by using the primers shown in Table 2, wherein 1787bp bands should be obtained by PCR in wild type mice, and about 700-800bp bands should be obtained in knockout mice.
TABLE 2 Tks4 Gene knock-out mouse identification primers
The system used for PCR amplification is a system with 20 mu L of mouse tail DNA solution 1 mu L, Taq enzyme 0.5 mu L, dNTPs 1 mu L, primers 1 mu L and Buffer 10 mu L respectively, and distilled water 5.5 mu L; the reaction procedure is as follows: 94 ℃ for 2 min; 10s at 98 ℃, 30s at 67 ℃ (-0.7 ℃/cycle), 1kb/min at 68 ℃ and 15 cycles; 10s at 98 ℃, 30s at 56 ℃, 1kb/min at 68 ℃ and 25 cycles; 10min at 68 ℃; storing at 4 ℃.
The PCR results showed that, among the six F0-generation mice obtained, the 6 mouse showed the results of homozygous knockout, the 1, 2, 3 and 5 mice showed the results of heterozygous knockout, and the PCR results of the other mouse were identical to that of the wild type (fig. 4).
To determine the specific knock-out fragment, the genomes of mice from generations 1, 2, 3 and 5 of F0 were sequenced and the results showed that each mouse had a deletion of a different fragment length.
TABLE 3 sequencing of the F0 mouse genome
In which F0 generation 5 mice were mated with C57BL6 mice to obtain stably inherited F1 generation mice, two of the F1 generation 2 and 4 mice were Tks4 +/-mice, and the remainder were Tks4+/+ (FIG. 5). The Tks4 gene of No.2 and No.4 mice is sequenced and identified, and the size of the fragment knocked out by the offspring mouse is consistent with that of the parent and is 1200 bp.
Example 3
Detection of knockout efficiency of Tks4 gene knockout mouse
After F2-generation mice were obtained by mating the F1-generation heterozygous mice obtained in example 2 with C57 mice, Tks4 +/-heterozygote was made to mate with each other, and F3 mice were obtained, and genotype identification was performed using two pairs of primers shown in Table 1, and the genotype of the mice was judged as wild type, heterozygous knockout type, and homozygous knockout type by PCR bands (shown as A in FIG. 6, for example). After obtaining a homozygous mouse, protein samples of brain, heart, lung, liver and other regions of a Tks4# 2 gene knock-out mouse and a littermate wild type # 4 mouse are extracted, and the knock-out condition of a Tks4 gene knock-out mouse is verified by a Tks4 antibody (B in figure 6), and the result shows that the Tks4 protein cannot be detected at each part of the knock-out mouse. This result demonstrates the success of the construction of the Tks4 gene knock-out mouse.
In fig. 6, a is to identify the progeny of the Tks4 gene knock-out mouse, and firstly, primers in table 1 are used to verify whether the genomic DNA of the progeny mouse contains a Tks4 fragment after knock-out, and the band after knock-out is 768 bp. Primers (F: GAAGGGCATTCTAACACACCTGTCA and R: GAAAGCTCAAAAGCTGCAAGAGACC) are then used to verify whether the genomic DNA of the progeny mouse contains the wild type, the band is 366bp, and the PCR identification results of the wild type mouse, the heterozygous mouse and the homozygous knockout mouse are shown in the figure respectively. Western Blot experiment examined whether Tks4 was completely knocked out in Tks4 knock-out mice of generation F3, and completed knock-out of Tks4 was confirmed in brain, lung and heart of mice by using littermate wild-type mice as controls.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and decorations can be made without departing from the principle of the present invention, and these modifications and decorations should also be regarded as the protection scope of the present invention.
Sequence listing
<110> northeast university
<120> construction method of Tks4 gene knock-out mouse
<160> 17
<170> SIPOSequenceListing 1.0
<210> 1
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 1
ctgttgtaac tcgccaatga 20
<210> 2
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 2
tggtcgtata aagatggtgc 20
<210> 3
<211> 4107
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 3
atggacaaga agtacagcat cggcctggac atcggcacca actctgtggg ctgggccgtg 60
atcaccgacg agtacaaggt gcccagcaag aaattcaagg tgctgggcaa caccgaccgg 120
cacagcatca agaagaacct gatcggagcc ctgctgttcg acagcggcga aacagccgag 180
gccacccggc tgaagagaac cgccagaaga agatacacca gacggaagaa ccggatctgc 240
tatctgcaag agatcttcag caacgagatg gccaaggtgg acgacagctt cttccacaga 300
ctggaagagt ccttcctggt ggaagaggat aagaagcacg agcggcaccc catcttcggc 360
aacatcgtgg acgaggtggc ctaccacgag aagtacccca ccatctacca cctgagaaag 420
aaactggtgg acagcaccga caaggccgac ctgcggctga tctatctggc cctggcccac 480
atgatcaagt tccggggcca cttcctgatc gagggcgacc tgaaccccga caacagcgac 540
gtggacaagc tgttcatcca gctggtgcag acctacaacc agctgttcga ggaaaacccc 600
atcaacgcca gcggcgtgga cgccaaggcc atcctgtctg ccagactgag caagagcaga 660
cggctggaaa atctgatcgc ccagctgccc ggcgagaaga agaatggcct gttcggaaac 720
ctgattgccc tgagcctggg cctgaccccc aacttcaaga gcaacttcga cctggccgag 780
gatgccaaac tgcagctgag caaggacacc tacgacgacg acctggacaa cctgctggcc 840
cagatcggcg accagtacgc cgacctgttt ctggccgcca agaacctgtc cgacgccatc 900
ctgctgagcg acatcctgag agtgaacacc gagatcacca aggcccccct gagcgcctct 960
atgatcaaga gatacgacga gcaccaccag gacctgaccc tgctgaaagc tctcgtgcgg 1020
cagcagctgc ctgagaagta caaagagatt ttcttcgacc agagcaagaa cggctacgcc 1080
ggctacattg acggcggagc cagccaggaa gagttctaca agttcatcaa gcccatcctg 1140
gaaaagatgg acggcaccga ggaactgctc gtgaagctga acagagagga cctgctgcgg 1200
aagcagcgga ccttcgacaa cggcagcatc ccccaccaga tccacctggg agagctgcac 1260
gccattctgc ggcggcagga agatttttac ccattcctga aggacaaccg ggaaaagatc 1320
gagaagatcc tgaccttccg catcccctac tacgtgggcc ctctggccag gggaaacagc 1380
agattcgcct ggatgaccag aaagagcgag gaaaccatca ccccctggaa cttcgaggaa 1440
gtggtggaca agggcgcttc cgcccagagc ttcatcgagc ggatgaccaa cttcgataag 1500
aacctgccca acgagaaggt gctgcccaag cacagcctgc tgtacgagta cttcaccgtg 1560
tataacgagc tgaccaaagt gaaatacgtg accgagggaa tgagaaagcc cgccttcctg 1620
agcggcgagc agaaaaaggc catcgtggac ctgctgttca agaccaaccg gaaagtgacc 1680
gtgaagcagc tgaaagagga ctacttcaag aaaatcgagt gcttcgactc cgtggaaatc 1740
tccggcgtgg aagatcggtt caacgcctcc ctgggcacat accacgatct gctgaaaatt 1800
atcaaggaca aggacttcct ggacaatgag gaaaacgagg acattctgga agatatcgtg 1860
ctgaccctga cactgtttga ggacagagag atgatcgagg aacggctgaa aacctatgcc 1920
cacctgttcg acgacaaagt gatgaagcag ctgaagcggc ggagatacac cggctggggc 1980
aggctgagcc ggaagctgat caacggcatc cgggacaagc agtccggcaa gacaatcctg 2040
gatttcctga agtccgacgg cttcgccaac agaaacttca tgcagctgat ccacgacgac 2100
agcctgacct ttaaagagga catccagaaa gcccaggtgt ccggccaggg cgatagcctg 2160
cacgagcaca ttgccaatct ggccggcagc cccgccatta agaagggcat cctgcagaca 2220
gtgaaggtgg tggacgagct cgtgaaagtg atgggccggc acaagcccga gaacatcgtg 2280
atcgaaatgg ccagagagaa ccagaccacc cagaagggac agaagaacag ccgcgagaga 2340
atgaagcgga tcgaagaggg catcaaagag ctgggcagcc agatcctgaa agaacacccc 2400
gtggaaaaca cccagctgca gaacgagaag ctgtacctgt actacctgca gaatgggcgg 2460
gatatgtacg tggaccagga actggacatc aaccggctgt ccgactacga tgtggaccat 2520
atcgtgcctc agagctttct gaaggacgac tccatcgaca acaaggtgct gaccagaagc 2580
gacaagaacc ggggcaagag cgacaacgtg ccctccgaag aggtcgtgaa gaagatgaag 2640
aactactggc ggcagctgct gaacgccaag ctgattaccc agagaaagtt cgacaatctg 2700
accaaggccg agagaggcgg cctgagcgaa ctggataagg ccggcttcat caagagacag 2760
ctggtggaaa cccggcagat cacaaagcac gtggcacaga tcctggactc ccggatgaac 2820
actaagtacg acgagaatga caagctgatc cgggaagtga aagtgatcac cctgaagtcc 2880
aagctggtgt ccgatttccg gaaggatttc cagttttaca aagtgcgcga gatcaacaac 2940
taccaccacg cccacgacgc ctacctgaac gccgtcgtgg gaaccgccct gatcaaaaag 3000
taccctaagc tggaaagcga gttcgtgtac ggcgactaca aggtgtacga cgtgcggaag 3060
atgatcgcca agagcgagca ggaaatcggc aaggctaccg ccaagtactt cttctacagc 3120
aacatcatga actttttcaa gaccgagatt accctggcca acggcgagat ccggaagcgg 3180
cctctgatcg agacaaacgg cgaaaccggg gagatcgtgt gggataaggg ccgggatttt 3240
gccaccgtgc ggaaagtgct gagcatgccc caagtgaata tcgtgaaaaa gaccgaggtg 3300
cagacaggcg gcttcagcaa agagtctatc ctgcccaaga ggaacagcga taagctgatc 3360
gccagaaaga aggactggga ccctaagaag tacggcggct tcgacagccc caccgtggcc 3420
tattctgtgc tggtggtggc caaagtggaa aagggcaagt ccaagaaact gaagagtgtg 3480
aaagagctgc tggggatcac catcatggaa agaagcagct tcgagaagaa tcccatcgac 3540
tttctggaag ccaagggcta caaagaagtg aaaaaggacc tgatcatcaa gctgcctaag 3600
tactccctgt tcgagctgga aaacggccgg aagagaatgc tggcctctgc cggcgaactg 3660
cagaagggaa acgaactggc cctgccctcc aaatatgtga acttcctgta cctggccagc 3720
cactatgaga agctgaaggg ctcccccgag gataatgagc agaaacagct gtttgtggaa 3780
cagcacaagc actacctgga cgagatcatc gagcagatca gcgagttctc caagagagtg 3840
atcctggccg acgctaatct ggacaaagtg ctgtccgcct acaacaagca ccgggataag 3900
cccatcagag agcaggccga gaatatcatc cacctgttta ccctgaccaa tctgggagcc 3960
cctgccgcct tcaagtactt tgacaccacc atcgaccgga agaggtacac cagcaccaaa 4020
gaggtgctgg acgccaccct gatccaccag agcatcaccg gcctgtacga gacacggatc 4080
gacctgtctc agctgggagg cgactaa 4107
<210> 4
<211> 25
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 4
gaagggcatt ctaacacacc tgtca 25
<210> 5
<211> 25
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 5
cagaggccaa ccaagagaga gaagc 25
<210> 6
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 6
taccatggag ccgtccctcc 20
<210> 7
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 7
catgcataca gcataggacc 20
<210> 8
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 8
caacatgtcg ctctgtattc 20
<210> 9
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 9
cgtgtgagat accacaaaac 20
<210> 10
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 10
gtggctcatg catacagcat 20
<210> 11
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 11
cagagcatac aagaattgag 20
<210> 12
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 12
gctctacacc cgtgtcacaa 20
<210> 13
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 13
tgagaatggt cgtataaaga 20
<210> 14
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 14
aaggaggaac tgggtcccgg 20
<210> 15
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 15
gccagatctg ggatgcaaac 20
<210> 16
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 16
catttatagg gatccaagaa 20
<210> 17
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 17
tgttgttgct catatatgac 20
Claims (7)
1. A construction method of a Tks4 gene knock-out mouse is characterized in that Cas9mRNA, sgRNA1 and sgRNA9 are introduced into fertilized eggs of a mouse, and the Tks4 gene of the mouse is knocked out by utilizing sgRNA1 and sgRNA9 to obtain a Tks4 gene knock-out mouse;
the nucleotide sequence of the sgRNA1 is shown in SEQ ID No.1, and the nucleotide sequence of the sgRNA9 is shown in SEQ ID No. 2;
the Tks4 gene knockout is realized by cutting a No.3 exon of the Tks4 gene.
2. The construction method of claim 1, wherein the sgRNA1 and the sgRNA9 are in a mass ratio of (0.5-1.5): (0.5-1.5).
3. The method for constructing the recombinant vector according to claim 2, wherein the sgRNA1 and the sgRNA9 are in a mass ratio of 1: 1.
4. The construction method according to claim 3, wherein the nucleotide sequence of the Cas9mRNA is shown as SEQ ID No. 3.
5. The construction method of claim 1, wherein the mass ratio of Cas9mRNA to sgRNA1 and sgRNA9 is (1.5-2.5): (0.3-0.8).
6. The construction method of claim 5, wherein the mass ratio of Cas9mRNA to sgRNA1 and sgRNA9 is 2:0.5: 0.5.
7. The construction method according to claim 1, wherein the Tks4 gene knock-out mouse is identified by using a primer pair, and the nucleotide sequences of the upstream and downstream primers of the primer pair are shown as SEQ ID No.4 and SEQ ID No.5 respectively.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011164525.0A CN112280803B (en) | 2020-10-27 | 2020-10-27 | Construction method of Tks4 gene knock-out mouse |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011164525.0A CN112280803B (en) | 2020-10-27 | 2020-10-27 | Construction method of Tks4 gene knock-out mouse |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112280803A CN112280803A (en) | 2021-01-29 |
CN112280803B true CN112280803B (en) | 2022-07-01 |
Family
ID=74373358
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011164525.0A Active CN112280803B (en) | 2020-10-27 | 2020-10-27 | Construction method of Tks4 gene knock-out mouse |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112280803B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115518160B (en) * | 2022-10-20 | 2023-09-08 | 东北师范大学 | Application of Tks4 inhibitor in preparation of obesity treatment drugs |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110885858B (en) * | 2019-11-01 | 2022-06-28 | 上海交通大学 | Construction method and application of Amy1 gene knockout mouse animal model |
-
2020
- 2020-10-27 CN CN202011164525.0A patent/CN112280803B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN112280803A (en) | 2021-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107760715B (en) | Transgenic vector and construction method and application thereof | |
Hay et al. | Human CC10 gene expression in airway epithelium and subchromosomal locus suggest linkage to airway disease | |
JP6190995B2 (en) | Simple and highly efficient method for producing genetically modified non-human mammals | |
US20180340176A1 (en) | Crispr-cas sgrna library | |
CN106282231B (en) | Construction method and application of mucopolysaccharide storage disease type II animal model | |
Hara et al. | Microinjection-based generation of mutant mice with a double mutation and a 0.5 Mb deletion in their genome by the CRISPR/Cas9 system | |
CN111690689B (en) | Construction method and application of humanized CCR2 gene modified animal model | |
Coulombe et al. | Multiple promoters and alternative splicing: Hoxa5 transcriptional complexity in the mouse embryo | |
CN115667283A (en) | RNA-guided kilobase-scale genome recombination engineering | |
US20190330660A1 (en) | Fel d 1 knockouts and associated compositions and methods based on crispr-cas9 genomic editing | |
US10932454B2 (en) | LDL receptor gene knockout, genetically-engineered hamster | |
CN110771573A (en) | Mouse animal model with knocked-in PirB gene and construction method thereof | |
CN112280803B (en) | Construction method of Tks4 gene knock-out mouse | |
CN111154758A (en) | Method for knocking out zebra fish slc26a4 gene | |
Yu et al. | Polymorphisms in the 5′ regulatory region of myostatin gene are associated with early growth traits in Yorkshire pigs | |
CN114410630B (en) | Construction method and application of TBC1D8B gene knockout mouse animal model | |
CN112342214A (en) | sgRNA sequence for targeted knockout of channel catfish zbtb38 gene and screening method thereof | |
CN111100877B (en) | Preparation method and application of hypertrophic cardiomyopathy mouse model | |
Wang et al. | Molecular characterization of porcine NECD, SNRPN and UBE3A genes and imprinting status in the skeletal muscle of neonate pigs | |
CN114591957A (en) | Construction method and application of severe hemophilia A animal model | |
CN115029352A (en) | Method for breeding adgrg1 gene-deleted zebra fish through gene knockout | |
Lin et al. | The copy number and integration site analysis of IGF-1 transgenic goat | |
CN108085324B (en) | Amplification of full-length sequence of sheep B4GALNT2 gene and detection of expression level thereof | |
CN114085840A (en) | Construction method of CAMTA2 gene-deleted zebra fish | |
CN113412820A (en) | Construction and application of multi-organ cell gene mutation detection gene editing mouse model |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |